SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
SPRUCE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$40.40+0.75 (+1.89%)
Close on Oct 19, 2026
- Market cap
- $98.22M
- P/E (TTM)
- –
- Dividend yield
- –
Spruce Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Market Cap | $116.11M | $164.85M |
| Enterprise Value | $26.90M | $87.06M |
| PB Ratio | 1.39 | 2.03 |
| P/TBV Ratio | 1.39 | 2.31 |
Income (trailing twelve months)
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Operating Income | -$47.83M | -$21.44M |
| Net Income | -$51.35M | -$22.46M |
| EBITDA | -$46.94M | -$16.91M |
| EPS (Diluted) | -$41.48 | -$0.83 |
Returns
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -106.0% | -53.1% |
| Return on Assets (ROA) | -82.4% | -41.0% |
| Return on Capital Employed (ROCE) | -52.0% | -37.8% |
Balance sheet
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $96.30M | $62.42M |
| Total Debt | $7.09M | $120.13M |
| Net Cash (Debt) | $89.21M | $15.68M |
| Net Cash Per Share | $31.04 | $0.66 |
| Equity (Book Value) | $83.73M | $48.79M |
| Book Value Per Share | $29.13 | $1.36 |
| Tangible Book Value | $83.73M | $23.06M |
| Working Capital | $90.19M | $75.77M |
Financial position
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Current Ratio | 9.23 | 3.30 |
| Quick Ratio | 8.78 | 2.39 |
| Debt / Equity | 0.08 | 0.51 |
| Interest Coverage | -26.63 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$42.62M | -$12.35M |
Efficiency
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Profits Per Employee | -$6.42M | -$703.34K |
| Employee Count | 8 | 74 |
Dividends and yields
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -44.2% | -22.7% |
Shares
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 2,874,010 | 58,179,650 |
| Shares Change (YoY) | 148.3% | 11.1% |
| Shares Change (QoQ) | 100.6% | 0.54% |
| Float | 813,385 | 49,173,100 |
| Shares Held by Insiders | 71.7% | 11.6% |
| Shares Held by Institutions | 69.7% | 59.4% |
Scores
| Measure | Spruce Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | -1.16 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Spruce Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.